192 related articles for article (PubMed ID: 20626711)
1. One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group.
Oshima K; Takahashi T; Mori T; Matsuyama T; Usuki K; Asano-Mori Y; Nakahara F; Okamoto S; Kurokawa M; Kanda Y
Transpl Infect Dis; 2010 Oct; 12(5):421-7. PubMed ID: 20626711
[TBL] [Abstract][Full Text] [Related]
2. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
Asano-Mori Y; Kanda Y; Oshima K; Kako S; Shinohara A; Nakasone H; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2008 Jun; 83(6):472-6. PubMed ID: 18266207
[TBL] [Abstract][Full Text] [Related]
3. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
Kanda Y; Mineishi S; Saito T; Saito A; Yamada S; Ohnishi M; Chizuka A; Niiya H; Suenaga K; Nakai K; Takeuchi T; Makimoto A; Tanosaki R; Kami M; Tanaka Y; Fujita S; Watanabe T; Kobayashi Y; Tobinai K; Takaue Y
Bone Marrow Transplant; 2001 Oct; 28(7):689-92. PubMed ID: 11704792
[TBL] [Abstract][Full Text] [Related]
4. Incidence and risk of postherpetic neuralgia after varicella zoster virus infection in hematopoietic cell transplantation recipients: Hokkaido Hematology Study Group.
Onozawa M; Hashino S; Haseyama Y; Hirayama Y; Iizuka S; Ishida T; Kaneda M; Kobayashi H; Kobayashi R; Koda K; Kurosawa M; Masauji N; Matsunaga T; Mori A; Mukai M; Nishio M; Noto S; Ota S; Sakai H; Suzuki N; Takahashi T; Tanaka J; Torimoto Y; Yoshida M; Fukuhara T
Biol Blood Marrow Transplant; 2009 Jun; 15(6):724-9. PubMed ID: 19450757
[TBL] [Abstract][Full Text] [Related]
5. The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation.
Thomson KJ; Hart DP; Banerjee L; Ward KN; Peggs KS; Mackinnon S
Bone Marrow Transplant; 2005 Jun; 35(11):1065-9. PubMed ID: 15806119
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation.
Kawamura K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Terasako K; Kimura S; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
Int J Infect Dis; 2014 Feb; 19():26-32. PubMed ID: 24211377
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders.
Kim DH; Messner H; Minden M; Gupta V; Kuruvilla J; Wright J; Lipton J
Transpl Infect Dis; 2008 Apr; 10(2):90-8. PubMed ID: 17605742
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for Varicella-Zoster virus infection after allogeneic peripheral blood stem cell transplantation.
Kim DH; Kumar D; Messner HA; Minden M; Gupta V; Kuruvilla J; Chae YS; Sohn SK; Lipton JH
Clin Transplant; 2008; 22(6):770-9. PubMed ID: 18707605
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of varicella zoster virus infection following allogeneic stem cell transplants].
Doki N; Hoshino T; Irisawa H; Sakura T; Miyawaki S
Rinsho Ketsueki; 2004 Oct; 45(10):1090-4. PubMed ID: 15553042
[TBL] [Abstract][Full Text] [Related]
10. Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation.
Leung TF; Chik KW; Li CK; Lai H; Shing MM; Chan PK; Lee V; Yuen PM
Bone Marrow Transplant; 2000 Jan; 25(2):167-72. PubMed ID: 10673675
[TBL] [Abstract][Full Text] [Related]
11. Varicella zoster virus meningoencephalitis after allogeneic hematopoietic stem cell transplantation.
Suzuki J; Ashizawa M; Okuda S; Wada H; Sakamoto K; Terasako K; Sato M; Kimura SI; Kikuchi M; Nakasone H; Kako S; Yamazaki R; Oshima K; Nishida J; Kanda Y
Transpl Infect Dis; 2012 Aug; 14(4):E7-12. PubMed ID: 22340704
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled trial of valacyclovir prophylaxis to prevent zoster recurrence from months 4 to 24 after BMT.
Klein A; Miller KB; Sprague K; DesJardin JA; Snydman DR
Bone Marrow Transplant; 2011 Feb; 46(2):294-9. PubMed ID: 20421867
[TBL] [Abstract][Full Text] [Related]
13. Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus disease after allogeneic hematopoietic stem cell transplantation.
Kawamura K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Terasako K; Kimura SI; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
Transpl Infect Dis; 2013 Oct; 15(5):457-65. PubMed ID: 23895431
[TBL] [Abstract][Full Text] [Related]
14. Visceral varicella zoster virus (VZV) after allogeneic hematopoietic stem cell transplant (HSCT) in pediatric patients with chronic graft-versus-host disease (cGVHD).
Peritz DC; Duncan C; Kurek K; Perez-Atayde AR; Lehmann LE
J Pediatr Hematol Oncol; 2008 Dec; 30(12):931-4. PubMed ID: 19131784
[TBL] [Abstract][Full Text] [Related]
15. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis.
Vusirikala M; Wolff SN; Stein RS; Brandt SJ; Morgan DS; Greer JP; Schuening FG; Dummer JS; Goodman SA
Bone Marrow Transplant; 2001 Aug; 28(3):265-70. PubMed ID: 11535994
[TBL] [Abstract][Full Text] [Related]
16. Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib.
Fukushima T; Sato T; Nakamura T; Iwao H; Nakajima A; Miki M; Sakai T; Kawanami T; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Okazaki T; Nakajima H; Motoo Y; Umehara H
Anticancer Res; 2012 Dec; 32(12):5437-40. PubMed ID: 23225448
[TBL] [Abstract][Full Text] [Related]
17. Clinical features and risk factors for developing varicella zoster virus dissemination following hematopoietic stem cell transplantation.
Umezawa Y; Kakihana K; Oshikawa G; Kobayashi T; Doki N; Sakamaki H; Ohashi K
Transpl Infect Dis; 2014 Apr; 16(2):195-202. PubMed ID: 24438510
[TBL] [Abstract][Full Text] [Related]
18. Long-term acyclovir prophylaxis for prevention of varicella zoster virus infection after autologous blood stem cell transplantation in patients with acute leukemia.
Sempere A; Sanz GF; Senent L; de la Rubia J; Jarque I; López F; Arilla MJ; Guinot M; Martín G; Martínez J
Bone Marrow Transplant; 1992 Dec; 10(6):495-8. PubMed ID: 1362686
[TBL] [Abstract][Full Text] [Related]
19. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir.
Steer CB; Szer J; Sasadeusz J; Matthews JP; Beresford JA; Grigg A
Bone Marrow Transplant; 2000 Mar; 25(6):657-64. PubMed ID: 10734301
[TBL] [Abstract][Full Text] [Related]
20. Visceral varicella zoster virus infection after allogeneic stem cell transplantation.
Doki N; Miyawaki S; Tanaka M; Kudo D; Wake A; Oshima K; Fujita H; Uehara T; Hyo R; Mori T; Takahashi S; Okamoto S; Sakamaki H;
Transpl Infect Dis; 2013 Jun; 15(3):314-8. PubMed ID: 23551634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
